Medication info

Cretap Tablet 5mg (Rosuvastatin Calcium)

Prescription medicationTabletApproval withdrawn
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
28 tablets (14 tablets/PTP packaging x 2), 30 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202001670 · Approved 2020.03.11

This product's status changed to Approval withdrawn on 2024.12.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication, and continue it throughout the treatment period. This medication may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams per day. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering this medication at 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: The safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of premature coronary heart disease
  • risk of stroke
View approved original text

This medication is primarily used to treat hypercholesterolemia and various dyslipidemias. It is taken as an adjunct when diet and exercise alone do not sufficiently control primary hypercholesterolemia and mixed hyperlipidemia, and is also used for homozygous familial hypercholesterolemia. It lowers total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis, and is beneficial for treating familial hypercholesterolemia in young children. Additionally, it assists dietary management in patients with dysbetalipoproteinemia and is effective in reducing the risk of cardiovascular diseases. In particular, it is used to reduce the risks of stroke, myocardial infarction, and arterial revascularization in middle-aged patients with elevated high-sensitivity C-reactive protein levels and additional risk factors. This medication is effective in improving lipid levels and protecting cardiovascular health.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication, and continue it throughout the treatment period. This medication may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams per day. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering this medication at 20 mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 6. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: The safety and efficacy in children under 10 years of age have not been established.

Precautions

This medication should not be used in certain patients. For example, it should not be administered to patients allergic to its components, those with severe liver impairment, patients with muscle disorders, patients taking specific concurrent medications, patients with severe renal impairment, or women who are pregnant or breastfeeding. Additionally, high-dose administration is prohibited in patients at high risk for muscle-related side effects. Since this medication contains lactose, patients with lactose intolerance should not take it. Regular monitoring of liver function and muscle status is necessary while taking this medication, especially if there is a history of excessive alcohol use or liver disease. If symptoms such as muscle pain, muscle weakness, or cramps occur, a doctor should be notified immediately, and in severe cases, discontinuation of the medication is required. In cases of acute severe illness or the onset of muscle weakness, the use of this medication should also be discontinued. There may be interactions with other medications, so any medications currently being taken should be reported to a doctor or pharmacist. Particularly, when combined with certain antiviral drugs, immunosuppressants, antibiotics, or fibrate class drugs, the risk of muscle side effects may increase. Women who may become pregnant should use adequate contraception, and those who are pregnant or breastfeeding should not take this medication. In case of overdose, there is no specific antidote, so treatment should be symptomatic, along with monitoring liver and muscle function. This medication generally does not significantly impair the ability to drive or operate machinery, but care should be taken as dizziness may occur. Lastly, this medication may result in higher systemic concentrations in Asians, so caution is needed in determining the dosage.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, drug eruption resembling lichen planus, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is best to store it at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer time.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

28 tablets (14 tablets/PTP packaging x 2), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.